Today: 9 April 2026
Subscribe
Browse Category

XETRA:HEI 10 November 2025

$100 B Bank Fraud Scandal Triggers Global Market Rout – DAX Sinks Below 24,000 Amid ‘Cockroach’ Fears

DAX Today (10 November 2025): German Stocks Jump on U.S. Shutdown Progress; Siemens Energy, Commerzbank, Hannover Re Lead Gains

Germany’s DAX jumped 1.8% to around 23,990 by late morning Monday as U.S. Senate progress on ending a 40-day government shutdown lifted global markets. Siemens Energy and Commerzbank rose about 5% after upgrades, while Hannover Re gained up to 4% on higher guidance. E.ON and Deutsche Telekom slipped. Eurozone Sentix morale dropped to −7.4, and Germany’s chemical sector sentiment hit a 30-year low.
10 November 2025
········

Stock Market Today

  • Avalyn Pharma Plans IPO to Fund Phase 3 Trials of Inhaled Respiratory Drugs
    April 9, 2026, 4:45 AM EDT. Avalyn Pharma, a Cambridge-based biotech, aims to raise funds through an IPO to advance inhaled formulations of approved lung drugs into phase 3 trials. The lead candidate, AP01, an inhaled form of pirfenidone for progressive pulmonary fibrosis, is in phase 2b. The company also pursues AP02, inhaled nintedanib, and plans preclinical work on AP03, a combination therapy. Avalyn has previously raised over $310 million, including $100 million in 2025, and holds $138 million in cash. CEO Lyn Baranowski brings experience from AstraZeneca-related respiratory drug development. The IPO follows a rebounding biotech market early in 2026, with peers like SpyGlass and Veradermics also focusing on new formulations of approved drugs.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 4:45 AM EDT Avalyn Pharma Plans IPO to Fund Phase 3 Trials of Inhaled Respiratory Drugs April 9, 2026, 4:45 AM EDT. Avalyn Pharma, a Cambridge-based biotech, aims to raise funds through an IPO to advance inhaled formulations of approved lung drugs into phase 3 trials. The lead candidate, AP01, an inhaled form of pirfenidone for progressive pulmonary fibrosis, is in phase 2b. The company also pursues AP02, inhaled nintedanib, and plans preclinical work on AP03, a combination therapy. Avalyn has previously raised over $310 million, including $100
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Go toTop